Age-dependent changes on fractalkine forms and their contribution to neurodegenerative diseases
- PMID: 37818457
- PMCID: PMC10561274
- DOI: 10.3389/fnmol.2023.1249320
Age-dependent changes on fractalkine forms and their contribution to neurodegenerative diseases
Abstract
The chemokine fractalkine (FKN, CX3CL1), a member of the CX3C subfamily, contributes to neuron-glia interaction and the regulation of microglial cell activation. Fractalkine is expressed by neurons as a membrane-bound protein (mCX3CL1) that can be cleaved by extracellular proteases generating several sCX3CL1 forms. sCX3CL1, containing the chemokine domain, and mCX3CL1 have high affinity by their unique receptor (CX3CR1) which, physiologically, is only found in microglia, a resident immune cell of the CNS. The activation of CX3CR1contributes to survival and maturation of the neural network during development, glutamatergic synaptic transmission, synaptic plasticity, cognition, neuropathic pain, and inflammatory regulation in the adult brain. Indeed, the various CX3CL1 forms appear in some cases to serve an anti-inflammatory role of microglia, whereas in others, they have a pro-inflammatory role, aggravating neurological disorders. In the last decade, evidence points to the fact that sCX3CL1 and mCX3CL1 exhibit selective and differential effects on their targets. Thus, the balance in their level and activity will impact on neuron-microglia interaction. This review is focused on the description of factors determining the emergence of distinct fractalkine forms, their age-dependent changes, and how they contribute to neuroinflammation and neurodegenerative diseases. Changes in the balance among various fractalkine forms may be one of the mechanisms on which converge aging, chronic CNS inflammation, and neurodegeneration.
Keywords: Alzheimer’s disease; CX3CL1; CX3CR1; Parkinson’s disease; aging; metalloproteases; neurodegenerative disease; neuroinflammation.
Copyright © 2023 Eugenín, Eugenín-von Bernhardi and von Bernhardi.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures



Similar articles
-
CX3CL1/CX3CR1 signaling targets for the treatment of neurodegenerative diseases.Pharmacol Ther. 2022 Mar;231:107989. doi: 10.1016/j.pharmthera.2021.107989. Epub 2021 Sep 4. Pharmacol Ther. 2022. PMID: 34492237 Review.
-
The Impact of the CX3CL1/CX3CR1 Axis in Neurological Disorders.Cells. 2020 Oct 13;9(10):2277. doi: 10.3390/cells9102277. Cells. 2020. PMID: 33065974 Free PMC article. Review.
-
Neuron-glia crosstalk in health and disease: fractalkine and CX3CR1 take centre stage.Open Biol. 2013 Dec 18;3(12):130181. doi: 10.1098/rsob.130181. Open Biol. 2013. PMID: 24352739 Free PMC article. Review.
-
Fractalkine/CX3CR1 is involved in the cross-talk between neuron and glia in neurological diseases.Brain Res Bull. 2019 Mar;146:12-21. doi: 10.1016/j.brainresbull.2018.11.017. Epub 2018 Nov 26. Brain Res Bull. 2019. PMID: 30496784 Review.
-
Fractalkine shedding is mediated by p38 and the ADAM10 protease under pro-inflammatory conditions in human astrocytes.J Neuroinflammation. 2016 Aug 22;13(1):189. doi: 10.1186/s12974-016-0659-7. J Neuroinflammation. 2016. PMID: 27549131 Free PMC article.
Cited by
-
Respiratory syncytial virus glycoprotein G impedes CX3CR1-activation by CX3CL1 and monocyte function.Npj Viruses. 2024 Dec 5;2(1):63. doi: 10.1038/s44298-024-00075-9. Npj Viruses. 2024. PMID: 40295855 Free PMC article.
-
Diagnostic potential of urinary CX3CL1 for amnestic mild cognitive impairment and Alzheimer's disease.Front Aging Neurosci. 2025 Jan 23;17:1501762. doi: 10.3389/fnagi.2025.1501762. eCollection 2025. Front Aging Neurosci. 2025. PMID: 39917031 Free PMC article.
-
Chronic administration of prebiotics and probiotics ameliorates pathophysiological hallmarks of Alzheimer's disease in a APP/PS1 transgenic mouse model.Front Pharmacol. 2024 Aug 6;15:1451114. doi: 10.3389/fphar.2024.1451114. eCollection 2024. Front Pharmacol. 2024. PMID: 39166107 Free PMC article.
-
CX3CL1 (Fractalkine)-CX3CR1 Axis in Inflammation-Induced Angiogenesis and Tumorigenesis.Int J Mol Sci. 2024 Apr 25;25(9):4679. doi: 10.3390/ijms25094679. Int J Mol Sci. 2024. PMID: 38731899 Free PMC article. Review.
-
Peripheral immune cell traits and Parkinson's disease: A Mendelian randomization study.PLoS One. 2024 Mar 5;19(3):e0299026. doi: 10.1371/journal.pone.0299026. eCollection 2024. PLoS One. 2024. PMID: 38442099 Free PMC article.
References
-
- Abrahamson M., Buttle D. J., Mason R. W., Hansson H., Grubb A., Lilja H., et al. . (1991a). Regulation of cystatin C activity by serine proteinases. Biomed. Biochim. Acta 50, 587–593. - PubMed
-
- Abrahamson M., Mason R. W., Hansson H., Buttle D. J., Grubb A., Ohlsson K. (1991b). Human cystatin C. role of the N-terminal segment in the inhibition of human cysteine proteinases and in its inactivation by leucocyte elastase. Biochem. J. 273, 621–626. doi: 10.1042/bj2730621, PMID: - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous